Lung Cancer Treatment Advances Reach 60% of US Patients

New targeted therapies and immunotherapies for lung cancer are now reaching over 60% of patients with advanced disease, a dramatic improvement in treatment access.

Fifteen states have enacted laws requiring insurance coverage for biomarker testing that helps match patients to lifesaving treatments.